Determining Elements of Anti-Fungal Immunity in BURN Patients
Assistance Publique - Hôpitaux de Paris
327 participants
Apr 23, 2025
OBSERVATIONAL
Conditions
Summary
Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.
Eligibility
Inclusion Criteria6
- Burn patients
- Adult patients ≥ 18 years old
- Admission < 4 days following burn injury
- Total burn surface Area ≥ 15%
- Non opposition of the patient or his/her relatives to the research
- Affiliation to social security or any health insurance
Exclusion Criteria3
- Pregnancy
- Opposition of the patient or his/her relatives
- Decision not to resuscitate or to limit or stop active therapies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites) At day 0, day 3, day 7, day 14, day 21
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06828458